342 related articles for article (PubMed ID: 34611482)
1. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
Doan HQ; Chen L; Nawas Z; Lee HH; Silapunt S; Migden M
Oncotarget; 2021 Sep; 12(20):2089-2100. PubMed ID: 34611482
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
[TBL] [Abstract][Full Text] [Related]
3. Novel Approaches in Non-Melanoma Skin Cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC).
Chmiel P; Kłosińska M; Forma A; Pelc Z; Gęca K; Skórzewska M
Cells; 2022 Oct; 11(20):. PubMed ID: 36291078
[TBL] [Abstract][Full Text] [Related]
4. Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma.
Lear JT; Dummer R; Guminski A
Oncotarget; 2021 Dec; 12(26):2531-2540. PubMed ID: 34966484
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
[TBL] [Abstract][Full Text] [Related]
6. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
7. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
8. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
9. Signaling Pathways and Therapeutic Strategies in Advanced Basal Cell Carcinoma.
Vallini G; Calabrese L; Canino C; Trovato E; Gentileschi S; Rubegni P; Tognetti L
Cells; 2023 Oct; 12(21):. PubMed ID: 37947611
[TBL] [Abstract][Full Text] [Related]
10. Sonidegib phosphate: new approval for basal cell carcinoma.
Tibes R
Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
Yin VT; Esmaeli B
Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma.
Lear JT; Morris LM; Ness DB; Lewis LD
Expert Rev Clin Pharmacol; 2023; 16(12):1211-1220. PubMed ID: 37975712
[TBL] [Abstract][Full Text] [Related]
15. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
16. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment.
Dessinioti C; Stratigos AJ
Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992360
[TBL] [Abstract][Full Text] [Related]
18. The current clinical approach to difficult-to-treat basal cell carcinomas.
Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
[TBL] [Abstract][Full Text] [Related]
19. A Novel Mechanism for Activation of GLI1 by Nuclear SMO That Escapes Anti-SMO Inhibitors.
Rahman MM; Hazan A; Selway JL; Herath DS; Harwood CA; Pirzado MS; Atkar R; Kelsell DP; Linton KJ; Philpott MP; Neill GW
Cancer Res; 2018 May; 78(10):2577-2588. PubMed ID: 29463581
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]